Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

26.21 -0.26 (-0.98%)
Streaming Delayed Price Updated: 9:37 AM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,695
Open 26.21
Bid (Size) 26.21 (100)
Ask (Size) 26.62 (100)
Prev. Close 26.47
Today's Range 26.21 - 26.58
52wk Range 8.245 - 53.65
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials ↗
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Announces $150 Million Registered Offering
From Maze Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-34.1%
-34.1%
1 Month
-9.6%
-9.6%
3 Month
-45.6%
-45.6%
6 Month
-13.4%
-13.4%
1 Year
+187.7%
+187.7%

More News

Read More
News headline image
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. ↗
Via The Motley Fool
Topics Regulatory Compliance
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗
Via The Motley Fool
Topics Regulatory Compliance
Wednesday's session: top gainers and losers ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
Via MarketBeat
News headline image
What's going on in today's session ↗
Via Chartmill

Frequently Asked Questions

Is Maze Therapeutics, Inc. - Common Stock publicly traded?
Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
What is the current price of Maze Therapeutics, Inc. - Common Stock?
The current price of Maze Therapeutics, Inc. - Common Stock is 26.21
When was Maze Therapeutics, Inc. - Common Stock last traded?
The last trade of Maze Therapeutics, Inc. - Common Stock was at 05/07/26 09:37 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.